SCHEMBL4638443

SCHEMBL4638443

COc1c(Br)cc(C)cc1-c1c(C)c(C(=O)O)cn1C

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 1/20 0.46
ALDH1A1 P00352 1/20 0.40
HPGD P15428 1/20 0.40
GPR35 Q9HC97 1/20 0.40
MYC P01106 1/20 0.39
TPMT P51580 1/20 0.38
LCK P06239 1/20 0.38
FYN P06241 1/20 0.38
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
TUBB4A P04350 4/20 0.34
TUBB P07437 4/20 0.34
TUBA3C P0DPH7 4/20 0.34
TUBA1B P68363 4/20 0.34
TUBA4A P68366 4/20 0.34
TUBB4B P68371 4/20 0.34
TUBB3 Q13509 4/20 0.34
TUBB2A Q13885 4/20 0.34
TUBB8 Q3ZCM7 4/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2444157 0.83 THRA (0.44) ALDH1A1MEN1KMT2AKDM4ELMNA
SCHEMBL7813116 0.75 HSD17B10 (0.71) HSD17B10ALDH1A1HPGDGPR35MYC
SCHEMBL4638617 0.70 HTT (0.46) HSD17B10ALDH1A1HPGDGPR35MEN1
SCHEMBL4891845 0.69 NOTUM (0.37) HSD17B10ALDH1A1HPGDMYCMEN1
SCHEMBL28799138 0.69 HSD17B10 (0.61) HSD17B10ALDH1A1HPGDGPR35TPMT
SCHEMBL4782578 0.68 ALDH1A1 (0.40) ALDH1A1MEN1KMT2AXDH
SCHEMBL7820121 0.68 HSD17B10 (0.50) HSD17B10ALDH1A1HPGDGPR35TPMT
SCHEMBL4892927 0.68 MYC (0.49) HSD17B10ALDH1A1HPGDMYCMEN1
SCHEMBL4639411 0.67 CA12 (0.45) HSD17B10ALDH1A1HPGDMYCMEN1
SCHEMBL4893584 0.66 NOTUM (0.39) GPR35MYCLCKFYNMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1773768-B1 PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS EXELIXIS INC (US) 2018-08-22 EP claimed
US-8367667-B2 Pyrrole derivatives as pharmaceutical agents EXELIXIS, INC. (US) 2013-02-05 US claimed
US-20110301128-A1 Pyrrole Derivatives As Pharmaceutical Agents EXELIXIS, INC. (US) 2011-12-08 US claimed
US-20080234270-A1 Pyrrole Derivatives As Pharmaceutical Agents EXELIXIS, INC. (US) 2008-09-25 US claimed
EP-1773768-A4 PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS EXELIXIS INC (US) 2008-08-06 EP claimed
EP-1773768-A2 PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS Exelixis, Inc. (US) 2007-04-18 EP claimed
WO-2006012642-A2 PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS EXELIXIS, INC. (US) 2006-02-02 WO claimed
EP-1773768-B1 PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS EXELIXIS INC (US) 2018-08-22 EP disclosed
EP-1844020-B1 HETEROCYCLIC CARBOXAMIDE COMPOUNDS AS STEROID NUCLEAR RECEPTOR LIGANDS EXELIXIS INC (US) 2017-09-06 EP disclosed
US-8367667-B2 Pyrrole derivatives as pharmaceutical agents EXELIXIS, INC. (US) 2013-02-05 US disclosed
US-20110301128-A1 Pyrrole Derivatives As Pharmaceutical Agents EXELIXIS, INC. (US) 2011-12-08 US disclosed
US-20080234270-A1 Pyrrole Derivatives As Pharmaceutical Agents EXELIXIS, INC. (US) 2008-09-25 US disclosed
EP-1773768-A4 PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS EXELIXIS INC (US) 2008-08-06 EP disclosed
EP-1844020-A1 HETEROCYCLIC CARBOXAMIDE COMPOUNDS AS STEROID NUCLEAR RECEPTOR LIGANDS Exelixis, Inc. (US) 2007-10-17 EP disclosed
EP-1773768-A2 PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS Exelixis, Inc. (US) 2007-04-18 EP disclosed
WO-2006076202-A1 HETEROCYCLIC CARBOXAMIDE COMPOUNDS AS STEROID NUCLEAR RECEPTORS LIGANDS EXELIXIS, INC. (US) 2006-07-20 WO disclosed
WO-2006012642-A2 PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS EXELIXIS, INC. (US) 2006-02-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110301128-A1 Pyrrole Derivatives As Pharmaceutical Agents PRLHR, PTGDR, TACR1 HSD17B10 2768/4885ALDH1A1 2251/4885HPGD 328/4885
US-20080234270-A1 Pyrrole Derivatives As Pharmaceutical Agents PRLHR, PTGDR, TACR1 HSD17B10 2768/4885ALDH1A1 2251/4885HPGD 328/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.